267875-80-9

Upstream product

• 267875-79-6 ethyl 3-(benzyloxy)-1-(2-(tert-butoxy)-2-oxoethyl)-6-methyl-2-oxo-1,2-dihydropyridine-4-carboxylate 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 267875-78-5 3-benzyloxy-6-methyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid ethyl ester 
• 49827-15-8 t-butyl iodoacetate 
• 267876-32-4 ethyl 3-hydroxy-6-methyl-2-oxo-1,2-dihydropyridine-4-carboxylate 

Downstream Products

• 267875-81-0 3-benzyloxy-4-diisobutylaminocarbonyl-6-methyl-1-tert-butyloxycarbonylmethyl-2-pyridinone 

Relevant academic research and scientific papers

TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

A compound of general formula (I): wherein: n is 1, 2 or 3; R1, R2, R3 and R4, independently represent OH or Q; and 20 Q represents a tissue-targeting moeity selected from the group consisting of or a stereoisomer, a hydrate, a solvate, or a salt thereof, or a mixture of same, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said 25 compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients.

Thrombin inhibitors

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, wherein b is NY or O; c is CY2or N; d is CY3or N; e is CY4or N; f is CY5or N; g is CY6or N; Y4, Y5, and Y6are independently hydrogen, C1-4alkyl, or halogen; Y1and Y2are independently hydrogen, C1-4alkyl, C3-7cycloalkyl, halogen, NH2, OH or C1-4alkoxy, and Y3is hydrogen, C1-4alkyl, C3-7cycloalkyl, halogen, —CN, NH2, OH or C1-4alkoxy; A is and W, W1, R1, R3, R4, R5, X and Z are defined in the specification.